Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pasithea Therapeutics Corp. on August 20, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Miami Beach, Florida. Its common stock (KTTA) and warrants (KTTAW) are listed on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards rather than financial performance.
Material Changes and Listing Status
- Non-Compliance Notice: On February 20, 2026, Nasdaq notified the Company of non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) due to a closing bid price below $1.00 for 30 consecutive business days.
- Initial Grace Period: The Company was initially granted a 180-day grace period ending August 19, 2026, to regain compliance.
- Extension Granted: On August 20, 2026, Nasdaq granted a second 180-day extension, moving the compliance deadline to February 16, 2027.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing bid price and may consider implementing a reverse stock split to regain compliance. The filing explicitly states there can be no assurance that the Company will meet the Minimum Bid Price Requirement during the extension period. Failure to regain compliance by February 16, 2027, will result in a notice of delisting, though the Company retains the right to appeal such a determination to a Nasdaq hearings panel.
Key Facts for Investor Verification
- Verify the current closing bid price of KTTA to assess the likelihood of meeting the $1.00 threshold by February 16, 2027.
- Monitor for any future announcements regarding a reverse stock split or other capital structure changes.
- Confirm the Company's cash position and runway, as the filing does not disclose financial metrics but implies potential liquidity constraints often associated with low stock prices.
- Review the Company's pipeline and clinical trial updates, as these are primary drivers for biotech stock valuation and potential price recovery.